ARiA VI 2017 - Looking to the Future

 

Could you in short explain the phenotypic variation we see in the TTR-FAP patient group?

Prof. Violaine Plante-Bordeneuve, University Hospital Henri Mondor, France
 

 

Penetrance varies depending on type of mutation, what is the ideal way of following an asymptomatic gene carrier?

Dr. Isabel Conceicão , Serviço de Neurologia Hospital de Santa Maria, Portugal
 

 

In finding the index patient with TTR-FAP, what are the key signs to look for?

Prof. Yasim Parman, Istanbul University Hospital, Turkey
 

 

How common is cardiac involvement in patients with TTR-FAP?

Dr. Pablo Garcia Pavá, Hospital Universitario Puerta de Hierro Majadahonda, Spain
 

 

In finding the index patient with TTR-FAP, what would you say are the most important key signs?

Dr. Lucia Galán, Hospital Clinico San Carlos, Spain
 

 

Could you describe the multi-organ nature of TTR-FAP?

Dr. Teresa Coelho, Santo António Hospital, Porto, Portugal
 

 

Paneldiskussion på ARiA 2017

Prof. David Adam, University Hospital, Bicetre, Paris Sud, France
Dr. Teresa Coelho, Santo António Hospital, Porto, Portugal
Dr. Jorge Mejia Baranda, Piteå Älvdals sjukhus, Sverige